Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...
Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...
Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...
Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...
The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...
What Is BCG Treatment for Bladder Cancer? Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer. BCG ...
Excitement is building as a new treatment for advanced bladder cancer that doubles survival time has been approved for NHS use. The new treatment combination includes enfortumab vedotin (Padcev) and ...
The "Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2025" report highlights significant R&D opportunities with over 20 companies and 22 pipeline drugs, focusing on innovative treatments like ...
TAR-200 achieved an 82% tumor elimination rate in high-risk non-muscle-invasive bladder cancer patients resistant to previous treatments. The device releases gemcitabine into the bladder over three ...
Bladder cancer affects approximately 83,000 Americans each year, yet remains one of the most overlooked forms of cancer despite having excellent survival rates when caught early. This disconnect ...
Cancer remains one of the most formidable health challenges of our time, affecting millions of Americans across all demographics. However, a troubling pattern has emerged within the Black community, ...
14d
Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present more than 30 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback